SCB

Dr. Douglas Carlson Announces Plans to Retire

Retrieved on: 
Thursday, May 25, 2023
Telecommunications, Other Manufacturing, Hardware, Consumer Electronics, Technology, Semiconductor, Manufacturing, Other Technology, MIT Lincoln Laboratory, Senior, U.S. Department of Defense Strategy for Operating in Cyberspace, Adventure, Research, MIT, Municipal Technical Advisory Service, Massachusetts Institute of Technology, SCB, MMIC, Silicon, Retirement, Publication, Bell Labs, Doctor of Science, Growth, Gallium arsenide, Medical device

MACOM Technology Solutions Holdings, Inc. (Nasdaq: MTSI) (“MACOM"), a leading supplier of semiconductor products, today announced Dr. Douglas Carlson, Senior Vice President, Technology, plans to retire at the beginning of MACOM’s next fiscal year.

Key Points: 
  • MACOM Technology Solutions Holdings, Inc. (Nasdaq: MTSI) (“MACOM"), a leading supplier of semiconductor products, today announced Dr. Douglas Carlson, Senior Vice President, Technology, plans to retire at the beginning of MACOM’s next fiscal year.
  • Dr. Carlson and the management team will work closely to ensure a smooth transition.
  • “I would like to acknowledge Dr. Douglas Carlson’s contributions to MACOM,” said Stephen G. Daly, President and Chief Executive Officer.
  • Dr. Carlson holds a ScB in Electronic Materials from Brown University and a ScD in Electronic Materials from MIT.

City Approves Design Of Bally's Chicago Casino

Retrieved on: 
Thursday, May 11, 2023
Food, Tribune, Gensler, Senior, Civil engineering, Farmer, Chicago casino proposals, IGB, Movement, Chicago Department of Transportation, NYSE, SITE Design Group, City, Collection, Nature, Restaurant, Architect, Site, SCB, Rendering (animal products), Riverwalk, Bally's Corporation, VIP, Amusement park, Hotel, Chicago River

PROVIDENCE, R.I., May 11, 2023 /PRNewswire/ -- Bally's Corporation (NYSE: BALY) today announced that the proposed site plan for Bally's Chicago Casino was approved by the Chicago Department of Planning and Urban Development on Wednesday, solidifying plans to begin construction on the mixed-use entertainment space in late 2024. The $1.7 billion development is projected to bring over 3,000 permanent jobs to the City.

Key Points: 
  • The $1.7 billion development is projected to bring over 3,000 permanent jobs to the City.
  • In addition, Bally's Chicago released renderings for its much-anticipated permanent casino resort development.
  • "Inspired by the city's interplay—grit and grandeur, structure and the organic, historically-charged and cutting-edge—the design of Bally's Chicago creates a sense of wonder and adventure accessible to everyone," said Bally's Senior Vice President of Design and Development Joyen Vakil.
  • "The unique and exciting design celebrates Chicago's motto, urbs in horto – city in a garden – and creates a dynamic public realm on site."

Taisys announces Proof of SIM Protocol to onboard billions of mobile phone users to the web3 society, bootstrapped by MetaDuet DAO.

Retrieved on: 
Wednesday, May 3, 2023
Communication, Financial Services Agency, Human, Partnership, SIM, Internet, RBI, OTT, Privacy, Creativity, Merkle, Reserve Bank of India, Ecosystem, SBT, SCB, Cryptocurrency, Mobile phone, Fintech, Ethereum

An open and decentralized ecosystem without intermediate and centralized systems is to be built for empowering the individuals.

Key Points: 
  • An open and decentralized ecosystem without intermediate and centralized systems is to be built for empowering the individuals.
  • With experiences in the SIM industry for 20 years, Taisys has announced the Proof of SIM protocol to introduce the mobile network into the web3 infrastructure, with "SIM Connected SBT" that is issued autonomously and transparently through Ethereum to a unique active SIM holder with zero knowledge proof.
  • In order to bootstrap the ecosystem, a MetaDuet DAO program will be launched for early adopters with Taisys SIM overlay technology in telco agnostic way.
  • "The future partnership with MNO/MVNOs for their SIM/eSIM integrated with PoSIM protocol will bring us to massive adoption.

SCB 10X Partners with Bloomberg for Fourth REDeFiNE Tomorrow Virtual Summit

Retrieved on: 
Wednesday, May 3, 2023
Synthetix, Osmosis, Decentralized finance, Digital technology, Entrepreneurship, Bloomberg, Compound, SCB, Investment, Cryptocurrency, Blockchain, Circle

BANGKOK, May 2, 2023 /PRNewswire/ -- SCB 10X ( https://scb10x.com/ ), the digital technology investment arm of SCBX Group, announced today the return of its annual REDeFiNE Tomorrow 2023.

Key Points: 
  • BANGKOK, May 2, 2023 /PRNewswire/ -- SCB 10X ( https://scb10x.com/ ), the digital technology investment arm of SCBX Group, announced today the return of its annual REDeFiNE Tomorrow 2023.
  • The global DeFi & Web 3.0 Virtual Summit will be held virtually May 25th -26th.
  • "Despite the past year's bear market, the industry has continued to innovate and create new opportunities, improving the space as a whole.
  • Last year's event, held over two days, brought in 40 speakers to an audience of 2,160 registered viewers.

SCB 10X Partners with Bloomberg for Fourth REDeFiNE Tomorrow Virtual Summit

Retrieved on: 
Wednesday, May 3, 2023
Synthetix, Osmosis, Decentralized finance, Digital technology, Entrepreneurship, Bloomberg, Compound, SCB, Investment, Cryptocurrency, Blockchain, Circle

BANGKOK, May 3, 2023 /PRNewswire/ -- SCB 10X ( https://scb10x.com/ ), the digital technology investment arm of SCBX Group, announced today the return of its annual REDeFiNE Tomorrow 2023.

Key Points: 
  • BANGKOK, May 3, 2023 /PRNewswire/ -- SCB 10X ( https://scb10x.com/ ), the digital technology investment arm of SCBX Group, announced today the return of its annual REDeFiNE Tomorrow 2023.
  • The global DeFi & Web 3.0 Virtual Summit will be held virtually May 25th -26th.
  • "Despite the past year's bear market, the industry has continued to innovate and create new opportunities, improving the space as a whole.
  • Last year's event, held over two days, brought in 40 speakers to an audience of 2,160 registered viewers.

Concept Medical received IDE approval to investigate safety and efficacy of its MagicTouch Sirolimus Coated Balloon Catheter for the treatment of small coronary artery disease

Retrieved on: 
Monday, May 1, 2023
Stent, Small Vessel, Investigational device exemption, Cardiac muscle, PTA, Restenosis, CAD, ISR, Revascularization, MACE, Trial of the century, PCI, Microangiopathy, Sirolimus, PMA, Patient, Physician, Risk, IDE, Coronary artery disease, FDA, SCB, Cutaneous small-vessel vasculitis, Drug-eluting stent, US FDA, Safety, Pharmaceutical industry, MD, TITAN

TAMPA, Fla., May 1, 2023 /PRNewswire/ -- The US FDA has granted an Investigational Device Exemption (IDE) approval for Concept Medical Inc's novel MagicTouch Sirolimus Coated Balloon (SCB) for the treatment of Small Vessels (SV) in coronary arteries.

Key Points: 
  • TAMPA, Fla., May 1, 2023 /PRNewswire/ -- The US FDA has granted an Investigational Device Exemption (IDE) approval for Concept Medical Inc's novel MagicTouch Sirolimus Coated Balloon (SCB) for the treatment of Small Vessels (SV) in coronary arteries.
  • US FDA, on the 25th of April 2023, granted the third IDE approval for Concept Medical's Sirolimus Coated Balloon – MagicTouch SCB.
  • Along with this latest IDE approval for the treatment of Small Vessel indication, Concept Medical received two other IDE approvals for the MagicTouch SCB family of products for the treatment of coronary In-Stent Restenosis (ISR) indication and Below-the-Knee indication (PTA).
  • The current IDE approval will allow Concept Medical to initiate pivotal clinical study to support safety and effectiveness of the MagicTouch SCB in small vessel coronary disease.

Concept Medical received IDE approval to investigate safety and efficacy of its MagicTouch Sirolimus Coated Balloon Catheter for the treatment of small coronary artery disease

Retrieved on: 
Monday, May 1, 2023
Stent, Small Vessel, Investigational device exemption, Cardiac muscle, PTA, Restenosis, CAD, ISR, Revascularization, MACE, Trial of the century, PCI, Microangiopathy, Sirolimus, PMA, Patient, Physician, Risk, IDE, Coronary artery disease, FDA, SCB, Cutaneous small-vessel vasculitis, Drug-eluting stent, US FDA, Safety, Pharmaceutical industry, MD, TITAN

TAMPA, Fla., May 1, 2023 /PRNewswire/ -- The US FDA has granted an Investigational Device Exemption (IDE) approval for Concept Medical Inc's novel MagicTouch Sirolimus Coated Balloon (SCB) for the treatment of Small Vessels (SV) in coronary arteries.

Key Points: 
  • TAMPA, Fla., May 1, 2023 /PRNewswire/ -- The US FDA has granted an Investigational Device Exemption (IDE) approval for Concept Medical Inc's novel MagicTouch Sirolimus Coated Balloon (SCB) for the treatment of Small Vessels (SV) in coronary arteries.
  • US FDA, on the 25th of April 2023, granted the third IDE approval for Concept Medical's Sirolimus Coated Balloon – MagicTouch SCB.
  • Along with this latest IDE approval for the treatment of Small Vessel indication, Concept Medical received two other IDE approvals for the MagicTouch SCB family of products for the treatment of coronary In-Stent Restenosis (ISR) indication and Below-the-Knee indication (PTA).
  • The current IDE approval will allow Concept Medical to initiate pivotal clinical study to support safety and effectiveness of the MagicTouch SCB in small vessel coronary disease.

DPR Construction Grows Mid-Atlantic Leadership

Retrieved on: 
Tuesday, March 21, 2023
DPR Construction, Construction, PE, Health, Civil engineering, Northeast Regional, Washington Metro, Attitude, SCB, Brown University, DPR, Growth, Management

COLUMBIA, Md., March 21, 2023 /PRNewswire/ -- DPR Construction, one of the nation's top technical builders, announces it has appointed Chris Hoffman, PE as Co-Business Unit Leader supporting the organization's offices in Washington, D.C. and Baltimore. With more than 15 years of experience in both preconstruction and the field, Hoffman will now support DPR teams and project delivery focused on self-perform work, prefabrication, virtual design and construction, and data.

Key Points: 
  • With more than 15 years of experience in both preconstruction and the field, Hoffman will now support DPR teams and project delivery focused on self-perform work, prefabrication, virtual design and construction, and data.
  • Under his leadership, the regional preconstruction team grew from a centralized team of 17 to a multi-market team of 70+ across five offices from Boston to Richmond.
  • Hoffman began his career as an intern at DPR in 2008 while attending Brown University, where he graduated Magna Cum Laude with a ScB in Civil Engineering and joined DPR full-time as an estimator.
  • The rapid expansion across the Northeast and in the Mid-Atlantic, under the leadership of Greg Haldeman, Northeast Regional Leader and Garcia, warranted additional support.

According to THE SAGE GROUP, High Restenosis Rates Following Endovascular Treatment of Infrapopliteal Disease Create a Significant Need for Improved Technologies

Retrieved on: 
Thursday, February 16, 2023
Science, Research, Health, Diabetes, Consulting, Medical Devices, Health Technology, Professional Services, DCB, Orchestra, Restenosis, TLR, MED, SLR, Patient, Incidence, Magic Touch, Stent, SAGE, SCB, DES, PCB, Safety, PAD, FDA, Sundance, Paclitaxel, Pharmaceutical industry

Recent research published by THE SAGE GROUP examines the challenges of infrapopliteal Peripheral Artery Disease (PAD) and incidence of restenosis.

Key Points: 
  • Recent research published by THE SAGE GROUP examines the challenges of infrapopliteal Peripheral Artery Disease (PAD) and incidence of restenosis.
  • “It is difficult to reach strong conclusions regarding device superiority for endovascular treatment of infrapopliteal disease,” stated Mary L. Yost, President of THE SAGE GROUP.
  • In addition to lesion length, these include primary efficacy end points, patient characteristics, lesion characteristics and morphology, as well as disease severity.
  • “In infrapopliteal disease, we believe that new, more effective endovascular devices are needed to reduce restenosis and improve patient outcomes.

Differentiated Capabilities of Surmodics’ Crystalline Drug Release Platform for Sirolimus-Coated Balloons Presented at ISET Conference

Retrieved on: 
Thursday, January 19, 2023
Medical Supplies, Health, Medical Devices, Surgery, Clinical Trials, Pharmaceutical, Cardiology, MS, CDR, SCB-125, ISET, PHD, Death, Sirolimus, Patient, Master of Medicine, International Symposium on Endovascular Therapy, PAD, SCB, Sundance, Pharmaceutical industry, FRACS, MBBS

The SWING trial is a first-in-human feasibility study of the Company’s Sundance™ SCB.

Key Points: 
  • The SWING trial is a first-in-human feasibility study of the Company’s Sundance™ SCB.
  • At ISET, SWING co-lead investigator Professor Ramon Varcoe, MBBS, MS, FRACS, PHD, MMed (ClinEpi), reinforced key findings from the SWING trial.
  • Rather than using encapsulation, the Sundance™ SCB delivers drug to target tissue via a coating of stable crystalline sirolimus with a proprietary excipient on the balloon surface, a method the Company describes as Crystalline Drug Release, or CDR.
  • When inflated, the Sundance™ SCB transfers this crystalline drug form to the vessel wall, whereupon the crystalized drug itself serves as the drug depot in a process that eliminates the need for a polymer depot.